Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aziyo Biologics (ELUT)
NASDAQ:ELUT
Aziyo Biologics (ELUT) Stock Price & Analysis
52 Followers
ELUT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.10 - $5.24
Previous Close$4.38
Volume22.13K
Average Volume (3M)52.24K
Market Cap
$121.11M
Enterprise Value$130.57M
Total Cash (Recent Filing)$12.55M
Total Debt (Recent Filing)$22.01M
Price to Earnings (P/E)―
Beta-0.07
Next Earnings
Aug 07, 2024EPS Estimate
-$0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.64
Shares Outstanding24,349,914
10 Day Avg. Volume141,435
30 Day Avg. Volume52,240
Standard Deviation0.24
R-Squared0.02
Alpha-0.00600
Financial Highlights & Ratios
Price to Book (P/B)-1.39
Price to Sales (P/S)2.83
Price to Cash Flow (P/CF)-8.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.10
Enterprise Value/Gross Profit11.81
Enterprise Value/Ebitda-3.02
Forecast
1Y Price Target
$10.50Price Target Upside139.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Aziyo Biologics News
PremiumCompany Announcements
Aziyo Biologics Gains FDA Clearance for EluPro® Bioenvelope
Ownership Overview
69.06% Insiders
2.42% Mutual Funds
27.76% Other Institutional Investors
0.76% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ELUT FAQ
What was Aziyo Biologics’s price range in the past 12 months?
Aziyo Biologics lowest stock price was $1.10 and its highest was $5.24 in the past 12 months.
What is Aziyo Biologics’s market cap?
Currently, no data Available
When is Aziyo Biologics’s upcoming earnings report date?
Aziyo Biologics’s upcoming earnings report date is Aug 07, 2024 which is in 33 days.
How were Aziyo Biologics’s earnings last quarter?
Aziyo Biologics released its earnings results on May 09, 2024. The company reported -$0.75 earnings per share for the quarter, missing the consensus estimate of -$0.415 by -$0.335.
Is Aziyo Biologics overvalued?
According to Wall Street analysts Aziyo Biologics’s price is currently Undervalued.
Does Aziyo Biologics pay dividends?
Aziyo Biologics does not currently pay dividends.
What is Aziyo Biologics’s EPS estimate?
Aziyo Biologics’s EPS estimate is -$0.33.
How many shares outstanding does Aziyo Biologics have?
Aziyo Biologics has 23,211,508 shares outstanding.
What happened to Aziyo Biologics’s price movement after its last earnings report?
Aziyo Biologics reported an EPS of -$0.75 in its last earnings report, missing expectations of -$0.415. Following the earnings report the stock price went up 17.5%.
Which hedge fund is a major shareholder of Aziyo Biologics?
Among the largest hedge funds holding Aziyo Biologics’s share is Platinum Investment Management. It holds Aziyo Biologics’s shares valued at N/A.
---
Aziyo Biologics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.50 (139.73% Upside)
$10.50 (139.73% Upside)
Blogger Sentiment
Bullish
ELUT Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 188.2K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Positive
20 days / 200 days
Momentum
88.54%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-41.68%
Trailing 12-Months
Company Description
Aziyo Biologics
Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.
---
ELUT Company Deck
---
ELUT Earnings Call
Q1 2024
0:00 / 0:00
---
ELUT Stock 12 Month Forecast
Average Price Target
$10.50
▲(139.73% Upside)
Technical Analysis
Eagle Pharmaceuticals
―
TransMedics Group
―
Intellia Therapeutics
―
Sorrento Therapeutics
―
Best Analysts Covering ELUT
1 Year
1 Year Success Rate
10/10 ratings generated profit
1 Year Average Return
+99.23%
reiterated a buy rating 14 days ago
Copying Frank Takkinen's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +99.23% per trade.
---